Clostridium butyricum MIYAIRI 588 Modifies Bacterial Composition under Antibiotic-Induced Dysbiosis for the Activation of Interactions via Lipid Metabolism between the Gut Microbiome and the Host
, Yuka Yamagishi 1 and Hiroshige Mikamo 1,*Round 1
Reviewer 1 Report
The manuscript entitled “ Clostridium butyricum MIYAIRI 588 modifies bacterial composition under antibiotic-induced dysbiosis for the activation of interactions via lipid metabolism between the gut microbiome and the host” describes the role of Clostridium butyricum MIYAIRI 588 (CBM 588) in the protection of gut epithelial cells under antibiotic-induced dysbiosis by upregulating protectin D1 production in host colon tissue following G protein-coupled receptor (GPR) 120 activation The authors have focused on the metabolic function alterations of the gut microbiome after CBM 588 and protectin D1 administration to reveal the interaction between the host and gut microbiome through lipid metabolism during antibiotic-induced dysbiosis. The manuscript is well-written, methods are descriptive and easy to follow, figures are well-done, the results corroborate adequately with the hypothesis, and conclusions are well-derived from the results. The manuscript is suitable for publication in the present form.
Author Response
Thank you very much for reviewing our manuscript and offering valuable advice. We have addressed the reviewer’s comments and questions.
In the revised manuscript, we explained a part of the method in too much detail, so we moved the method of metabolome analysis by LC-MS/MS and HPLC, and Cell treatment to another document as a supplemental material. The supplemental material has been moved to the same file as the supplemental table. Thanks to reviewers’ comments, we think the quality of our manuscript is enhanced.
We look forward to hearing from you regarding this resubmission.
Reviewer 2 Report
Drs Ariyoshi and colleagues provide an extensive study of Clostridium Butyricum MIYAIRI 588 and its effect on intestinal lipid metabolites in the context of intestinal dysbiosis.
The study provides relevant insight into the cellular mechanisms underlying potentially beneficial effects of CBM588 on intestinal lipid metabolism and effects on gut microbiome.
The methods are described in great detail and the pictorial explanation help understanding the sequence of experimental steps.
The conclusions are valid and are based on the results that are presented.
Possibly, some of the methods could be deposited into a supplementary data file.
Author Response
Thank you very much for reviewing our manuscript and offering valuable advice. We have addressed the reviewer’s comments and questions.
In the revised manuscript, we explained a part of the method in too much detail, so we moved the method of metabolome analysis by LC-MS/MS and HPLC, and Cell treatment to another document as a supplemental material. The supplemental material has been moved to the same file as the supplemental table. Thanks to reviewers’ comments, we think the quality of our manuscript is enhanced.
We look forward to hearing from you regarding this resubmission.
